Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
December 2019
-
Media ReleaseNovartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMDIn two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-…
-
Media ReleaseNovartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing the risk of death by almost 30…
-
Media ReleaseNovartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world settingEfficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3 Fewer known CAR-T cell therapy…
-
Media ReleaseNovartis global survey uncovers profound and often under-reported effects on sickle cell disease patientsFindings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell disease and a pattern of not seeking care despite potentially life-…
-
Media ReleaseNovartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapyOnce-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1 QMF149 showed improvement in peak…
-
Media ReleaseNovartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D DayUniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms60 projects in Phase 2 pipeline with 10+ advancing…
-
Key ReleaseNovartis tender offer for The Medicines Company commencesBasel, December 5, 2019 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation (“Purchaser”), has…
-
Media ReleaseNovartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platformsWith more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM-3 immunotherapy, with decitabine on preliminary response rates in…
November 2019
-
Key ReleaseNovartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of deathOver 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL…
-
Media ReleaseNovartis launches Innovation Prize for Assistive Tech to encourage new technologies that address unmet needs of the multiple sclerosis communityThe Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) identifies and embraces technology that aims to improve mobility and daily life for people living with MS Applications are…
-
Media ReleaseNovartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEFEntresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated…
-
Key ReleaseNew Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell diseaseSickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.…
Pagination
- ‹ Previous page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- …
- 100
- › Next page